Meropenem Kabi

Meropenem, the active ingredient in Meropenem Kabi, is a carbapenem antibiotic presented as a sterile powder for intravenous use. It is employed to treat severe bacterial infections in hospitalized adults and children, including infections caused by multi‑drug‑resistant Gram‑negative and Gram‑positive organisms.

GNH USA supplies Meropenem Kabi as a licensed, GDP‑compliant international pharmaceutical product, serving hospitals, transplant centres and pharmacies worldwide with reliable quality and regulatory conformity. The company adheres to EU GMP standards and provides cold‑chain logistics for the sterile formulation.

Meropenem is used for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infection: eradicates mixed aerobic and anaerobic pathogens, improving clinical cure rates. - Hospital‑acquired pneumonia, including ventilator‑associated pneumonia: provides broad coverage against resistant Gram‑negative organisms. - Complicated urinary tract infection: eliminates causative bacteria, facilitating resolution of symptoms. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat susceptible pathogens. - Sepsis and febrile neutropenia: offers rapid bactericidal activity in systemic infections.

Meropenem may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional emesis. - Rash: transient skin erythema. - Headache: mild discomfort. - Elevated liver enzymes: transient transaminase rise.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: acute hypersensitivity reaction requiring immediate treatment. - Clostridioides difficile‑associated colitis: severe diarrhea due to bacterial overgrowth. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: acute kidney injury in susceptible individuals. - Hypersensitivity syndrome: systemic rash, fever, organ involvement.

When using Meropenem, clinicians should observe several safety considerations. - Renal function: adjust dosage in patients with impaired renal clearance. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Pregnancy: prescribe only if the potential benefit justifies the potential risk to the fetus. - Concomitant valproic acid: monitor for reduced seizure control due to decreased valproate levels. - Superinfection: watch for secondary fungal or C. difficile infections during therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate concentrations, risking seizure breakthrough. - Probenecid: may increase meropenem plasma levels, heightening toxicity risk. - Other carbapenems: concurrent use can increase neurotoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics (e.g., furosemide): combined nephrotoxic potential requires renal function monitoring. - Aminoglycosides: additive renal toxicity warrants dose adjustment and close monitoring. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, necessitating INR checks.